P511 In silico trials in human ventricular and purkinje cell models predict safety and efficacy of 10 antiarrhythmic drugs
Safety and efficacy of antiarrhythmic drugs are still a great challenge in cardiology. Drug-induced EP changes in both Purkinje and ventricular cardiomyocytes have been implicated in arrhythmogenesis in vivo, and can be investigated through human-based computer models.
Main Authors: | Trovato, C, Passini, E, Tissier, A, Nagy, N, Varro', A, Severi, S, Rodriguez, B |
---|---|
Format: | Journal article |
Published: |
Oxford University Press
2017
|
Similar Items
-
Human Purkinje in silico model enables mechanistic investigations into automaticity and pro-arrhythmic abnormalities
by: Trovato, C, et al.
Published: (2020) -
Cross clinical-experimental-computational qualification of in silico drug trials on human cardiac purkinje cells for proarrhythmia risk prediction
by: Cristian Trovato, et al.
Published: (2022-10-01) -
Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach
by: Paci, M, et al.
Published: (2017) -
Interactions that matter: 10 Antiarrhythmic drugs
by: Aronson, J
Published: (1987) -
Antiarrhythmic Drug Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy
by: Sean P. Gaine, et al.
Published: (2023-04-01)